424 related articles for article (PubMed ID: 32322001)
1. The premise of personalized immunotherapy for cancer dormancy.
Manjili MH
Oncogene; 2020 May; 39(22):4323-4330. PubMed ID: 32322001
[TBL] [Abstract][Full Text] [Related]
2. Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets.
Aqbi HF; Coleman C; Zarei M; Manjili SH; Graham L; Koblinski J; Guo C; Xie Y; Guruli G; Bear HD; Idowu MO; Habibi M; Wang XY; Manjili MH
Breast Cancer Res; 2020 Oct; 22(1):116. PubMed ID: 33115528
[TBL] [Abstract][Full Text] [Related]
3. The inherent premise of immunotherapy for cancer dormancy.
Manjili MH
Cancer Res; 2014 Dec; 74(23):6745-9. PubMed ID: 25411346
[TBL] [Abstract][Full Text] [Related]
4. A Theoretical Basis for the Efficacy of Cancer Immunotherapy and Immunogenic Tumor Dormancy: The Adaptation Model of Immunity.
Manjili MH
Adv Cancer Res; 2018; 137():17-36. PubMed ID: 29405975
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic cancer vaccines: From initial findings to prospects.
Song Q; Zhang CD; Wu XH
Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
[TBL] [Abstract][Full Text] [Related]
6. Cell dormancy and tumor refractory.
Wang K; Jiang W; Cheng C; Li Y; Tu M
Anticancer Agents Med Chem; 2013 Feb; 13(2):1312-1316. PubMed ID: 22934702
[TBL] [Abstract][Full Text] [Related]
7. New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target?
Goss P; Allan AL; Rodenhiser DI; Foster PJ; Chambers AF
APMIS; 2008; 116(7-8):552-68. PubMed ID: 18834402
[TBL] [Abstract][Full Text] [Related]
8. [Identification of cancer-stem cell antigens and development of CTL-mediated cancer immunotherapy].
Miyamoto S; Kanaseki T; Hirohashi Y; Tsukahara T; Kikuchi Y; Sato N; Torigoe T
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):40-47. PubMed ID: 28539553
[TBL] [Abstract][Full Text] [Related]
9. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach.
Kim CG; Sang YB; Lee JH; Chon HJ
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360800
[TBL] [Abstract][Full Text] [Related]
10. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
11. Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?
Quesnel B
Expert Rev Vaccines; 2006 Dec; 5(6):773-81. PubMed ID: 17184216
[TBL] [Abstract][Full Text] [Related]
12. Metastases in immune-mediated dormancy: a new opportunity for targeting cancer.
Romero I; Garrido F; Garcia-Lora AM
Cancer Res; 2014 Dec; 74(23):6750-7. PubMed ID: 25411345
[TBL] [Abstract][Full Text] [Related]
13. Tumor dormancy and cancer stem cells: two sides of the same coin?
Kleffel S; Schatton T
Adv Exp Med Biol; 2013; 734():145-79. PubMed ID: 23143979
[TBL] [Abstract][Full Text] [Related]
14. Personalized Cancer Vaccines Advance in the Clinic.
Schmidt C
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29095978
[No Abstract] [Full Text] [Related]
15. Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications.
Rossari F; Zucchinetti C; Buda G; Orciuolo E
Cell Oncol (Dordr); 2020 Apr; 43(2):155-176. PubMed ID: 31392521
[TBL] [Abstract][Full Text] [Related]
16. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Ward JP; Gubin MM; Schreiber RD
Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
[TBL] [Abstract][Full Text] [Related]
17. Neoantigen Vaccines Pass the Immunogenicity Test.
Linette GP; Carreno BM
Trends Mol Med; 2017 Oct; 23(10):869-871. PubMed ID: 28867556
[TBL] [Abstract][Full Text] [Related]
18. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
[TBL] [Abstract][Full Text] [Related]
19. Multifaceted kinetics of immuno-evasion from tumor dormancy.
d'Onofrio A
Adv Exp Med Biol; 2013; 734():111-43. PubMed ID: 23143978
[TBL] [Abstract][Full Text] [Related]
20. Targeting neoantigens to augment antitumour immunity.
Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM
Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
